STSG-0002
/ Staidson Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
December 19, 2023
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
(clinicaltrials.gov)
- P2 | N=9 | Terminated | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | N=32 ➔ 9 | Trial completion date: Mar 2029 ➔ Dec 2023 | Recruiting ➔ Terminated; The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
Enrollment change • Trial completion date • Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation
December 19, 2023
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
(clinicaltrials.gov)
- P2 | N=9 | Terminated | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | N=32 ➔ 9 | Trial completion date: Mar 2029 ➔ Dec 2023 | Recruiting ➔ Terminated; The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
Enrollment change • Trial completion date • Trial termination • Hepatitis B • Hepatology • Infectious Disease • Inflammation
May 16, 2023
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
(clinicaltrials.gov)
- P2 | N=32 | Recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation
May 16, 2023
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
(clinicaltrials.gov)
- P2 | N=32 | Recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation
March 08, 2023
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
(clinicaltrials.gov)
- P2 | N=32 | Not yet recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd
New P2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
March 08, 2023
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
(clinicaltrials.gov)
- P2 | N=32 | Not yet recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd
New P2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 6
Of
6
Go to page
1